In the ongoing civil fraud trial, the legal team of former President Donald Trump has rejected the comparison of their client to notorious “Pharma Bro” Martin Shkreli, labeling it as ‘irresponsible’. The verdict is anticipated by January 31.
Trump’s defense team has refuted all allegations, contending that the inflated valuations were a result of Trump’s business acumen. The trial follows a partial summary judgment that found Trump had submitted “fraudulent valuations” for his assets.
On Tuesday, New York Attorney General Letitia James cited a ruling involving Martin Shkreli, arguing for a lifetime real estate ban for Trump. Defense attorney Clifford Robert responded on Wednesday, calling the comparison “misplaced and irresponsible.”
Robert argued that Trump’s fraud case lacks witnesses, complaints, and victims compared to Shkreli’s case. He also warned of the “sobering future consequences” of the Attorney General’s “shameless abuse of power.”
Trump attorney Chris Kise reportedly said that the ruling in Trump’s case could have far-reaching implications for the New York business community. He urged major bank CEOs and Wall Street participants to speak out against the Attorney General’s “shocking and tyrannical interference in the capital markets.”
Trump’s case has been contentious, with the former President proclaiming his innocence in court and invoking his Fifth Amendment rights during a deposition by New York Attorney General lawyers. The outcome of this case could set a precedent for future fraud cases involving high-profile business figures.
Photo Courtesy: Shutterstock.com
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
